Update on Dr Reddy's FDA warning letter

Dr Reddy's has submitted response to the US regulator's warning letter

id-100146211

Dr Reddy's has received a warning letter issued by the US FDA on November 05

Dr Reddy's Laboratories (DRL) has submitted a response to the US Food and Drug Administration (US FDA) on December 7, 2015, the firm said in a filing to BSE.

Dr Reddy's has received a warning letter issued by the US FDA on November 05, 2015 relating to its API manufacturing facilities at Srikakulam, Andhra Pradesh and Miryalaguda, Telangana, as well as Oncology Formulation manufacturing facility at Duvvada, Visakhapatnam, Andhra Pradesh.

In response to the letter, Mr G V Prasad, CEO, DRL said, "We are in the process of shifting some of the products from these plants to other facilities and considering third party assessment for its plants."

 

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X